In individuals who are able to adhere to combination antiretroviral therapy (ART), therapy suppresses human immunodeficiency virus (HIV) replication, restores immune function, and prevents the development of acquired immunodeficiency syndrome (AIDS) (Deeks et al., 2013). More than 20 different antiretroviral drugs belonging to six main classes are currently approved for clinical use (Pau and George, 2014). Depending on the class, these drugs block different steps of the HIV replication cycle, such as reverse transcription, proviral integration, or virus particle maturation. Current ART regimens typically consist of two nucleotide or nucleoside reverse transcriptase inhibitors (NRTIs) and a third drug of another class, for example, a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), or an integrase strand transfer inhibitor (INSTI).

Despite the efficient suppression of HIV replication, ART is not curative and has to be sustained lifelong. Persistence of viral reservoirs forms the major obstacle to an HIV cure (Deeks et al., 2016). Viral reservoir markers, such as low-level HIV RNA in plasma (residual viremia) and cell-associated (CA) HIV DNA and RNA, can be measured in most treated individuals with plasma HIV RNA suppressed to below the limit of quantification of commercial assays (Jacobs et al., 2019; Pasternak and Berkhout, 2018; Pasternak et al., 2013; Avettand-Fènoël et al., 2016; Sharaf and Li, 2017). Although HIV latent reservoirs persist primarily by cell longevity and proliferation (Chomont et al., 2009; Maldarelli et al., 2014; Wagner et al., 2014), replenishment of the reservoirs by residual virus replication despite ART has been proposed as an alternative mechanism of HIV persistence (Chun et al., 2005; Lorenzo-Redondo et al., 2016; Sigal et al., 2011). The latter possibility remains a matter of longstanding debate in HIV research field (Martinez-Picado and Deeks, 2016). Residual HIV replication can result from insufficient penetration of antiretroviral drugs into tissues and anatomic sanctuaries, causing reduced local drug concentrations in tissue sites (Estes et al., 2017; Fletcher et al., 2014). However, most (but not all) studies could not demonstrate any measurable virus evolution in peripheral blood and tissues of ART-treated individuals (Bozzi et al., 2019; Van Zyl et al., 2017; Joos et al., 2008). This lack of significant virus evolution on ART is considered one of the strongest arguments against residual HIV replication. On the other hand, a transient increase in episomal HIV DNA has been demonstrated in a number of trials of ART intensification with raltegravir, an INSTI (Buzón et al., 2010; Hatano et al., 2013a). This accumulation of unintegrated HIV DNA, observed upon blocking integration, revealed ongoing integration events prior to intensification. Because all other antiretroviral drug classes act upstream of INSTIs, this implies that complete rounds of HIV replication (infection of new cells) had been ongoing pre-intensification. However, no decrease in residual HIV viremia could be demonstrated in these and other intensification trials (Gandhi et al., 2010; McMahon et al., 2010; Hatano et al., 2011).

It is also a matter of debate whether different ART regimens are equally potent in suppressing residual HIV replication. All current antiretroviral drugs act by preventing the infection of new cells and are not expected to inhibit HIV RNA transcription or virus production in the long-lived reservoir cells that were infected prior to ART initiation, or in the progeny of such cells. Therefore, if regimens are equally potent in stopping the infection of new cells, one would not expect to detect a difference in residual viremia or CA RNA levels between ART regimens. Consequently, finding such a difference would suggest that some regimens are more potent in suppressing residual replication than others, arguing that virus suppression is less complete with at least some of the regimens. A number of studies reported lower levels of residual viremia in individuals treated with NNRTI-based, compared to PI-based, ART regimens (Geretti et al., 2019; Darcis et al., 2020a, reviewed in Darcis et al., 2020b). However, to date, few studies have compared levels of CA HIV reservoir markers between different ART regimens (Nicastri et al., 2008; Sarmati et al., 2012; Kiselinova et al., 2015). Here, we cross-sectionally measured CA HIV RNA and DNA in two cohorts of individuals receiving suppressive ART containing two NRTIs and either an NNRTI or a PI.

In this study, we demonstrated in two independent cohorts of individuals on suppressive ART that NNRTI-based triple ART regimens are associated with lower levels of CA HIV RNA compared with PI-based regimens. To the best of our knowledge, this is the largest study comparing CA HIV RNA levels between individuals on different ART regimens. Although several studies have compared residual viremia between ART regimens and most have found lower levels in NNRTI-treated than in PI-treated individuals (Darcis et al., 2020b), very few groups included other HIV reservoir markers in such comparisons. Nicastri et al., 2008 reported lower total HIV DNA levels in individuals treated with PI-based regimens and Sarmati et al., 2012 found no difference in the HIV DNA level by regimen, despite the fact that both studies reported higher residual viremia in PI-treated individuals. Kiselinova et al., 2015 performed a matched case-control study comparing nevirapine and PIs for residual viremia, total and episomal HIV DNA, and CA HIV RNA and did not find any differences by regimen for any of these markers. Notably, the latter study matched participants for the duration of PI-based or nevirapine-based regimens, but despite this, significant differences were still observed between the nevirapine- and PI-treated groups in total ART duration and duration of plasma HIV RNA suppression. In our study, we reasoned that, in the absence of a priori knowledge of the factors associated with CA HIV levels, such matching, albeit potentially reducing confounding, could introduce a selective bias and the results would therefore not be representative of the total ART-treated population. Instead, we chose for a cohort study design, controlling for a number of factors in the multivariable models.

Among all demographic and clinical variables, only duration of current regimen and duration of virological suppression were associated with the ART regimen, being longer in NNRTI- than in PI-treated individuals. This can be explained by the fact that while efavirenz and nevirapine, the drugs used by the absolute majority of our NNRTI-treated individuals, were approved for medical use in the late 1990s, modern PIs like atazanavir and darunavir, which were used by most of our PI-treated individuals, were only approved in the mid- or late 2000s. This means that most of the NNRTI-treated individuals in this study started ART, or switched to NNRTIs from the first-generation PIs, earlier than the PI-treated individuals. Because the HIV reservoir generally decays with time on ART (Siliciano et al., 2003), this association of duration of suppression with the ART regimen could have potentially confounded the association of the ART regimen with the HIV reservoir measures such as CA RNA and DNA. Indeed, we found that both these HIV markers were negatively associated with the duration of suppression in the AIMS cohort. Interestingly, low-level plasma HIV RNA detectability in that cohort was also negatively associated with the duration of suppression (Figure 1—figure supplement 2), confirming the results of a previous study (Darcis et al., 2020a). However, to our surprise, no association of CA RNA or DNA with the duration of suppression was found in the COBRA cohort. One possible reason for this difference between the two cohorts is that the COBRA participants were on average much longer on ART than the AIMS participants (117.8 vs 47.1 months of cumulative virological suppression, respectively). Decay of the HIV reservoir after ART initiation is multiphasic (Perelson et al., 1997; Blankson et al., 2000), and while the long-term dynamics of CA RNA has not yet been studied in detail, reports on the dynamics of total HIV DNA and residual plasma viremia have demonstrated that these markers reach a plateau after 5–7 years of treatment (Palmer et al., 2008; Besson et al., 2014; Bachmann et al., 2019), possibly due to clonal expansion of the viral reservoir cells (Maldarelli et al., 2014; Wagner et al., 2014). If the same applies to CA RNA, then it may be expected that after several years on ART, this reservoir measure will also no longer depend on the time on therapy, something that we indeed observed in the COBRA cohort. Instead, in the COBRA cohort, CA RNA and especially total DNA positively correlated with the plasma HIV RNA zenith, suggesting that even after a decade of ART, the HIV reservoir size is still partly determined by its pre-therapy values. Interestingly, most proviral DNA sequences from ART-treated individuals were recently shown to match circulating HIV variants detected shortly before the start of therapy, suggesting that the HIV reservoir quickly turns over in the untreated infection and that the reservoir that persists on ART has been primarily established at the start of therapy (Abrahams et al., 2019; Brodin et al., 2016; Pankau et al., 2020).

Another variable that could have confounded the association of the ART regimen with the HIV reservoir measures such as CA HIV RNA is the adherence to ART. Earlier studies have reported lower adherence among individuals treated with older PI-based ART regimens (O'Connor et al., 2013). However, we and others have not previously observed a difference in adherence between individuals treated with modern PI- and NNRTI-based regimens (Pasternak et al., 2015; Konstantopoulos et al., 2015), and in this study, adherence was also not associated with the therapy regimen. We have previously shown that modest non-adherence correlates with longitudinal changes in CA RNA (Pasternak et al., 2012). However, no significant association between adherence and CA RNA levels was observed in this study. Adherence was also not associated with low-level plasma HIV RNA detectability (Figure 1—figure supplement 2). The relation between adherence and CA HIV RNA or residual viremia is undoubtedly complex and deserves further research, but it must be noted that while in our previous report the adherence was measured over 1-week periods immediately prior to the HIV sampling moments, in this study we used 1-month adherence measurements taken within 20 days from the sampling moments. Whether short-term adherence is more strongly associated with CA RNA levels or residual viremia remains to be studied.

Notwithstanding the associations of CA RNA with other factors, in both cohorts, NNRTI-based ART was independently associated with lower CA RNA levels as compared with PI-based ART, as revealed by the multivariable analysis. This analysis revealed very similar effect sizes of the ART regimen on CA RNA in both cohorts, despite the fact that several factors, such as duration of virological suppression and the PI drugs, differed between the cohorts. On average, CA RNA levels were 1.75- to 2-fold lower in the NNRTI-treated participants. This confirms numerous reports that measured lower residual plasma viremia in NNRTI- compared to PI-treated individuals (Darcis et al., 2020b). In fact, also in this study, low-level plasma HIV RNA was more frequently detectable in PI-treated than in NNRTI-treated participants, despite no difference in therapy adherence by regimen. Notably, a recent large study of more than 12,000 participants starting ART revealed that PI-treated participants were on average 2.7 times more likely to experience virological failure compared with NNRTI-treated participants (El Bouzidi et al., 2020). Moreover, three independent clinical trials of triple ART intensification with raltegravir have previously demonstrated much stronger increases in episomal HIV DNA in PI- compared to NNRTI-treated participants, suggesting that at ‘baseline’, PI-treated individuals had higher levels of residual replication (Buzón et al., 2010; Hatano et al., 2013a; Hatano et al., 2011). Combined, this prior evidence and the results of this study strongly suggest that NNRTIs are more potent in suppressing HIV residual replication than PIs. Constant low-level viral replication, even if it does not cause the development of drug resistance and therapy failure, could exert continuous pressure on the immune system and cause additional morbidity as a result of persistent immune activation, inflammation, and immunosenescence (Klatt et al., 2013; Massanella et al., 2016). Several studies have reported excess morbidity and mortality rates in infected ART-treated individuals, compared with the general population (Schouten et al., 2014; Guaraldi et al., 2011; Lohse et al., 2007). Although it is still unclear whether this is due to the adverse effects of the antiretroviral drugs or due to the residual HIV activity, our results argue that an effort should be made to ensure HIV replication is maximally suppressed during therapy.

Interestingly, some NNRTIs, such as rilpivirine, efavirenz, and etravirine, but not nevirapine, can promote selective apoptosis of infected cells by inducing HIV protease-mediated cytotoxicity (Trinité et al., 2019). If these NNRTIs are present in cells that are actively producing viral proteins, they may bind to the reverse transcriptase portion of a newly translated Gag-Pol polyprotein and promote its homodimerization, resulting in premature protease activation. This leads to induction of apoptosis and pyroptosis, as well as CARD8 inflammasome activation (Figueiredo et al., 2006; Jochmans et al., 2010; Wang et al., 2021). However, it is very unlikely that such NNRTI effects could contribute to the levels of CA RNA in our cohorts, for two reasons. First, for this mechanism to work, a cell has to express HIV Gag-Pol, and cells that express HIV proteins without ex vivo stimulation are exceedingly rare in ART-treated individuals (Pardons et al., 2019). Second, nevirapine, in comparison with other NNRTIs, has no such activity (Trinité et al., 2019; Figueiredo et al., 2006; Wang et al., 2021), but in our study, nevirapine was associated with the same levels of CA RNA as efavirenz, and another study showed even lower levels of residual plasma viremia in nevirapine-treated compared to efavirenz-treated individuals (Haïm-Boukobza et al., 2011). This argues against induction of apoptosis of infected cells being a plausible mechanism behind the more pronounced virological suppression by NNRTIs.

Replenishment of the HIV reservoir by residual virus replication has been proposed as one of the mechanisms of HIV persistence (Chun et al., 2005). The association of the ART regimen with total HIV DNA in this study was similar to its association with CA RNA: in both cohorts, levels of total DNA were 1.8-fold lower in the NNRTI-treated participants. This suggests that persistent residual replication in the PI-treated participants may have resulted in a larger viral reservoir. However, this has to be interpreted with caution, as no single marker can at present provide a reliable estimate of the HIV reservoir size (Sharaf and Li, 2017). Moreover, different definitions of the HIV reservoir exist. Although total HIV DNA is mostly composed of genetically defective proviruses and thus its measurements overestimate the replication-competent reservoir (Bruner et al., 2016), these defective proviruses can be transcribed, translated, and even produce defective viral particles, and therefore can contribute to chronic immune activation and inflammation despite ART (Pollack et al., 2017; Imamichi et al., 2020; Imamichi et al., 2016; Finzi et al., 2006). Therefore, it has been proposed to extend the definition of the reservoir to all infected cells that can contribute to the residual HIV pathogenesis (Avettand-Fènoël et al., 2016; Baxter et al., 2018). Furthermore, both total HIV DNA and CA HIV RNA have been shown to predict the time to viral rebound after ART interruption (Williams et al., 2014; Li et al., 2016), and we have recently reported that CA HIV RNA was predictive of both time to and magnitude of viral rebound after interruption of temporary ART initiated during primary HIV infection (Pasternak et al., 2020). This argues that despite being partially composed of defective proviruses, the transcription-competent reservoir does reflect the replication-competent reservoir (Baxter et al., 2018; Abdel-Mohsen et al., 2020). In view of our present results, future studies should investigate the effects of different ART regimens on the replication-competent reservoir, as the latter is the main obstacle for the development of an HIV cure (Pasternak and Berkhout, 2016). Interestingly, Li et al., 2016 demonstrated that NNRTI-treated individuals experienced a significantly longer time to viral rebound after ART interruption. This may suggest lower replication-competent reservoirs in individuals treated with NNRTI-based ART regimens, although longer half-lives of NNRTIs, leading to prolonged NNRTI exposure after treatment interruption, provide a plausible additional explanation.

Our study has some limitations. First, we did not include individuals treated with INSTI-based ART, which is currently recommended as the first-line therapy (https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/11/what-to-start), because such individuals were rare (<5%) in the COBRA cohort and absent from the AIMS cohort. Studies in more recent cohorts are necessary to elucidate the differences in CA HIV markers between INSTI-based ART and other regimens. It must be noted that although NNRTI- and PI-based ART regimens are no longer recommended as the first-line therapy in all settings, millions of infected individuals are still treated with these regimens. Thus, our results are relevant for the clinical management of these individuals. Second, although our results provide strong evidence that individuals treated with PI-based ART undergo residual HIV replication, this evidence remains indirect as the direct demonstration of infection of new cells in an ART-treated individual is extremely difficult if not impossible. Therefore, although studies have used various approaches to prove or disprove the existence of residual replication on ART (reviewed in Pasternak et al., 2013; Martinez-Picado and Deeks, 2016), all these approaches have so far been indirect. Third, although we adjusted our models for a number of clinical parameters, the observational nature of these cohorts means that residual confounding cannot be entirely excluded. For instance, PI-based regimens could have been preferentially prescribed to individuals with a worse viro-immunological profile and/or expected poor therapy adherence, because PIs impose a relatively high genetic barrier to resistance and consequently will be more ‘forgiving’ to non-adherence. However, we did not observe any significant differences by regimen in plasma HIV RNA zenith, current and nadir CD4+ count, or therapy adherence, arguing against such a ‘prescription bias’. In this regard, a clinical trial with a factorial design, in which participants would switch from PI-based to NNRTI-based ART regimens and vice versa, would be important to confirm our findings.

In summary, here we have demonstrated in two independent cohorts that levels of HIV reservoir markers are lower in individuals treated with NNRTI- as compared to PI-based combination ART. We have previously proposed CA RNA as a sensitive marker of the active HIV reservoir and residual replication (Pasternak et al., 2013), a role that is further reinforced by the results of this study. Monitoring of CA RNA levels to detect residual HIV activity despite ART is warranted in order to prevent possible ART complications such as persistent immune activation or therapy failure (Pasternak et al., 2009; El Bouzidi et al., 2020; Hatano et al., 2013b), especially in individuals treated with PI-based regimens.

All data generated or analysed during this study are included in the manuscript and supporting files.

1. 1. Abdel-Mohsen M
   2. Richman D
   3. Siliciano RF
   4. Nussenzweig MC
   5. Howell BJ
   6. Martinez-Picado J
   7. Chomont N
   8. Bar KJ
   9. Yu XG
   10. Lichterfeld M
   11. Alcami J
   12. Hazuda D
   13. Bushman F
   14. Siliciano JD
   15. Betts MR
   16. Spivak AM
   17. Planelles V
   18. Hahn BH
   19. Smith DM
   20. Ho YC
   21. Buzon MJ
   22. Gaebler C
   23. Paiardini M
   24. Li Q
   25. Estes JD
   26. Hope TJ
   27. Kostman J
   28. Mounzer K
   29. Caskey M
   30. Fox L
   31. Frank I
   32. Riley JL
   33. Tebas P
   34. Montaner LJ
   35. BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection

   (2020) Recommendations for measuring HIV reservoir size in cure-directed clinical trials

   Nature Medicine 26:1339–1350.

   https://doi.org/10.1038/s41591-020-1022-1

   • PubMed
   • Google Scholar
2. 1. Abrahams MR
   2. Joseph SB
   3. Garrett N
   4. Tyers L
   5. Moeser M
   6. Archin N
   7. Council OD
   8. Matten D
   9. Zhou S
   10. Doolabh D
   11. Anthony C
   12. Goonetilleke N
   13. Karim SA
   14. Margolis DM
   15. Pond SK
   16. Williamson C
   17. Swanstrom R

   (2019) The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation

   Science Translational Medicine 11:eaaw5589.

   https://doi.org/10.1126/scitranslmed.aaw5589

   • PubMed
   • Google Scholar
3. 1. Avettand-Fènoël V
   2. Hocqueloux L
   3. Ghosn J
   4. Cheret A
   5. Frange P
   6. Melard A
   7. Viard JP
   8. Rouzioux C

   (2016) Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications

   Clinical Microbiology Reviews 29:859–880.

   https://doi.org/10.1128/CMR.00015-16

   • PubMed
   • Google Scholar
4. 1. Bachmann N
   2. von Siebenthal C
   3. Vongrad V
   4. Turk T
   5. Neumann K
   6. Beerenwinkel N
   7. Bogojeska J
   8. Fellay J
   9. Roth V
   10. Kok YL
   11. Thorball CW
   12. Borghesi A
   13. Parbhoo S
   14. Wieser M
   15. Böni J
   16. Perreau M
   17. Klimkait T
   18. Yerly S
   19. Battegay M
   20. Rauch A
   21. Hoffmann M
   22. Bernasconi E
   23. Cavassini M
   24. Kouyos RD
   25. Günthard HF
   26. Metzner KJ
   27. Swiss HIV Cohort Study

   (2019) Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART

   Nature Communications 10:3193.

   https://doi.org/10.1038/s41467-019-10884-9

   • PubMed
   • Google Scholar
5. 1. Baxter AE
   2. O'Doherty U
   3. Kaufmann DE

   (2018) Beyond the replication-competent HIV reservoir: transcription and translation-competent reservoirs

   Retrovirology 15:18.

   https://doi.org/10.1186/s12977-018-0392-7

   • PubMed
   • Google Scholar
6. 1. Besson GJ
   2. Lalama CM
   3. Bosch RJ
   4. Gandhi RT
   5. Bedison MA
   6. Aga E
   7. Riddler SA
   8. McMahon DK
   9. Hong F
   10. Mellors JW

   (2014) HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy

   Clinical Infectious Diseases 59:1312–1321.

   https://doi.org/10.1093/cid/ciu585

   • PubMed
   • Google Scholar
7. 1. Blankson JN
   2. Finzi D
   3. Pierson TC
   4. Sabundayo BP
   5. Chadwick K
   6. Margolick JB
   7. Quinn TC
   8. Siliciano RF

   (2000) Biphasic decay of latently infected CD4+ T cells in acute human immunodeficiency virus type 1 infection

   The Journal of Infectious Diseases 182:1636–1642.

   https://doi.org/10.1086/317615

   • PubMed
   • Google Scholar
8. 1. Boom R
   2. Sol CJ
   3. Salimans MM
   4. Jansen CL
   5. Wertheim-van Dillen PM
   6. van der Noordaa J

   (1990) Rapid and simple method for purification of nucleic acids

   Journal of Clinical Microbiology 28:495–503.

   https://doi.org/10.1128/jcm.28.3.495-503.1990

   • PubMed
   • Google Scholar
9. 1. Bozzi G
   2. Simonetti FR
   3. Watters SA
   4. Anderson EM
   5. Gouzoulis M
   6. Kearney MF
   7. Rote P
   8. Lange C
   9. Shao W
   10. Gorelick R
   11. Fullmer B
   12. Kumar S
   13. Wank S
   14. Hewitt S
   15. Kleiner DE
   16. Hattori J
   17. Bale MJ
   18. Hill S
   19. Bell J
   20. Rehm C
   21. Grossman Z
   22. Yarchoan R
   23. Uldrick T
   24. Maldarelli F

   (2019) No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: implications for HIV eradication

   Science Advances 5:eaav2045.

   https://doi.org/10.1126/sciadv.aav2045

   • PubMed
   • Google Scholar
10. 1. Brodin J
    2. Zanini F
    3. Thebo L
    4. Lanz C
    5. Bratt G
    6. Neher RA
    7. Albert J

    (2016) Establishment and stability of the latent HIV-1 DNA reservoir

    eLife 5:e18889.

    https://doi.org/10.7554/eLife.18889

    • PubMed
    • Google Scholar
11. 1. Bruner KM
    2. Murray AJ
    3. Pollack RA
    4. Soliman MG
    5. Laskey SB
    6. Capoferri AA
    7. Lai J
    8. Strain MC
    9. Lada SM
    10. Hoh R
    11. Ho YC
    12. Richman DD
    13. Deeks SG
    14. Siliciano JD
    15. Siliciano RF

    (2016) Defective proviruses rapidly accumulate during acute HIV-1 infection

    Nature Medicine 22:1043–1049.

    https://doi.org/10.1038/nm.4156

    • PubMed
    • Google Scholar
12. 1. Buzón MJ
    2. Massanella M
    3. Llibre JM
    4. Esteve A
    5. Dahl V
    6. Puertas MC
    7. Gatell JM
    8. Domingo P
    9. Paredes R
    10. Sharkey M
    11. Palmer S
    12. Stevenson M
    13. Clotet B
    14. Blanco J
    15. Martinez-Picado J

    (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

    Nature Medicine 16:460–465.

    https://doi.org/10.1038/nm.2111

    • PubMed
    • Google Scholar
13. 1. Chomont N
    2. El-Far M
    3. Ancuta P
    4. Trautmann L
    5. Procopio FA
    6. Yassine-Diab B
    7. Boucher G
    8. Boulassel MR
    9. Ghattas G
    10. Brenchley JM
    11. Schacker TW
    12. Hill BJ
    13. Douek DC
    14. Routy JP
    15. Haddad EK
    16. Sékaly RP

    (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation

    Nature Medicine 15:893–900.

    https://doi.org/10.1038/nm.1972

    • PubMed
    • Google Scholar
14. 1. Chun TW
    2. Nickle DC
    3. Justement JS
    4. Large D
    5. Semerjian A
    6. Curlin ME
    7. O'Shea MA
    8. Hallahan CW
    9. Daucher M
    10. Ward DJ
    11. Moir S
    12. Mullins JI
    13. Kovacs C
    14. Fauci AS

    (2005) HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir

    Journal of Clinical Investigation 115:3250–3255.

    https://doi.org/10.1172/JCI26197

    • PubMed
    • Google Scholar
15. 1. Darcis G
    2. Maes N
    3. Pasternak AO
    4. Sauvage AS
    5. Frippiat F
    6. Meuris C
    7. Uurlings F
    8. Lecomte M
    9. Léonard P
    10. Elmoussaoui M
    11. Fombellida K
    12. Vaira D
    13. Moutschen M

    (2020a) Detectability of HIV residual viremia despite therapy is highly associated with treatment with a protease Inhibitor-Based combination antiretroviral therapy

    Antimicrobial Agents and Chemotherapy 64:e01902-19.

    https://doi.org/10.1128/AAC.01902-19

    • Google Scholar
16. 1. Darcis G
    2. Berkhout B
    3. Pasternak AO

    (2020b) Differences in HIV markers between infected individuals treated with different ART regimens: implications for the persistence of viral reservoirs

    Viruses 12:489.

    https://doi.org/10.3390/v12050489

    • Google Scholar
17. 1. de Bruin M
    2. Hospers HJ
    3. van Breukelen GJ
    4. Kok G
    5. Koevoets WM
    6. Prins JM

    (2010) Electronic monitoring-based counseling to enhance adherence among HIV-infected patients: a randomized controlled trial

    Health Psychology 29:421–428.

    https://doi.org/10.1037/a0020335

    • PubMed
    • Google Scholar
18. 1. De Francesco D
    2. Underwood J
    3. Post FA
    4. Vera JH
    5. Williams I
    6. Boffito M
    7. Sachikonye M
    8. Anderson J
    9. Mallon PW
    10. Winston A
    11. Sabin CA
    12. POPPY study group

    (2016) Defining cognitive impairment in people-living-with-HIV: the POPPY study

    BMC Infectious Diseases 16:617.

    https://doi.org/10.1186/s12879-016-1970-8

    • PubMed
    • Google Scholar
19. 1. De Francesco D
    2. Wit FW
    3. Cole JH
    4. Kootstra NA
    5. Winston A
    6. Sabin CA
    7. Underwood J
    8. van Zoest RA
    9. Schouten J
    10. Kooij KW
    11. Prins M
    12. Guaraldi G
    13. Caan MWA
    14. Burger D
    15. Franceschi C
    16. Libert C
    17. Bürkle A
    18. Reiss P
    19. COmorBidity in Relation to AIDS (COBRA) collaboration

    (2018) The 'COmorBidity in Relation to AIDS' (COBRA) cohort: Design, methods and participant characteristics

    PLOS ONE 13:e0191791.

    https://doi.org/10.1371/journal.pone.0191791

    • PubMed
    • Google Scholar
20. 1. Deeks SG
    2. Lewin SR
    3. Havlir DV

    (2013) The end of AIDS: hiv infection as a chronic disease

    The Lancet 382:1525–1533.

    https://doi.org/10.1016/S0140-6736(13)61809-7

    • PubMed
    • Google Scholar
21. 1. Deeks SG
    2. Lewin SR
    3. Ross AL
    4. Ananworanich J
    5. Benkirane M
    6. Cannon P
    7. Chomont N
    8. Douek D
    9. Lifson JD
    10. Lo Y-R
    11. Kuritzkes D
    12. Margolis D
    13. Mellors J
    14. Persaud D
    15. Tucker JD
    16. Barre-Sinoussi F
    17. Alter G
    18. Auerbach J
    19. Autran B
    20. Barouch DH
    21. Behrens G
    22. Cavazzana M
    23. Chen Z
    24. Cohen EA
    25. Corbelli GM
    26. Eholié S
    27. Eyal N
    28. Fidler S
    29. Garcia L
    30. Grossman C
    31. Henderson G
    32. Henrich TJ
    33. Jefferys R
    34. Kiem H-P
    35. McCune J
    36. Moodley K
    37. Newman PA
    38. Nijhuis M
    39. Nsubuga MS
    40. Ott M
    41. Palmer S
    42. Richman D
    43. Saez-Cirion A
    44. Sharp M
    45. Siliciano J
    46. Silvestri G
    47. Singh J
    48. Spire B
    49. Taylor J
    50. Tolstrup M
    51. Valente S
    52. van Lunzen J
    53. Walensky R
    54. Wilson I
    55. Zack J

    (2016) International AIDS society global scientific strategy: towards an HIV cure 2016

    Nature Medicine 22:839–850.

    https://doi.org/10.1038/nm.4108

    • Google Scholar
22. 1. El Bouzidi K
    2. Jose S
    3. Phillips AN
    4. Pozniak A
    5. Ustianowski A
    6. Gompels M
    7. Winston A
    8. Schaap A
    9. Dunn DT
    10. Sabin CA
    11. UK CHIC Study

    (2020) First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines

    Aids 34:1823–1831.

    https://doi.org/10.1097/QAD.0000000000002603

    • PubMed
    • Google Scholar
23. 1. Estes JD
    2. Kityo C
    3. Ssali F
    4. Swainson L
    5. Makamdop KN
    6. Del Prete GQ
    7. Deeks SG
    8. Luciw PA
    9. Chipman JG
    10. Beilman GJ
    11. Hoskuldsson T
    12. Khoruts A
    13. Anderson J
    14. Deleage C
    15. Jasurda J
    16. Schmidt TE
    17. Hafertepe M
    18. Callisto SP
    19. Pearson H
    20. Reimann T
    21. Schuster J
    22. Schoephoerster J
    23. Southern P
    24. Perkey K
    25. Shang L
    26. Wietgrefe SW
    27. Fletcher CV
    28. Lifson JD
    29. Douek DC
    30. McCune JM
    31. Haase AT
    32. Schacker TW

    (2017) Defining total-body AIDS-virus burden with implications for curative strategies

    Nature Medicine 23:1271–1276.

    https://doi.org/10.1038/nm.4411

    • Google Scholar
24. 1. Figueiredo A
    2. Moore KL
    3. Mak J
    4. Sluis-Cremer N
    5. de Bethune MP
    6. Tachedjian G

    (2006) Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol

    PLOS Pathogens 2:e119.

    https://doi.org/10.1371/journal.ppat.0020119

    • PubMed
    • Google Scholar
25. 1. Finzi D
    2. Plaeger SF
    3. Dieffenbach CW

    (2006) Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis

    Clinical and Vaccine Immunology 13:715–721.

    https://doi.org/10.1128/CVI.00052-06

    • Google Scholar
26. 1. Fletcher CV
    2. Staskus K
    3. Wietgrefe SW
    4. Rothenberger M
    5. Reilly C
    6. Chipman JG
    7. Beilman GJ
    8. Khoruts A
    9. Thorkelson A
    10. Schmidt TE
    11. Anderson J
    12. Perkey K
    13. Stevenson M
    14. Perelson AS
    15. Douek DC
    16. Haase AT
    17. Schacker TW

    (2014) Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues

    PNAS 111:2307–2312.

    https://doi.org/10.1073/pnas.1318249111

    • PubMed
    • Google Scholar
27. 1. Gandhi RT
    2. Zheng L
    3. Bosch RJ
    4. Chan ES
    5. Margolis DM
    6. Read S
    7. Kallungal B
    8. Palmer S
    9. Medvik K
    10. Lederman MM
    11. Alatrakchi N
    12. Jacobson JM
    13. Wiegand A
    14. Kearney M
    15. Coffin JM
    16. Mellors JW
    17. Eron JJ
    18. AIDS Clinical Trials Group A5244 team

    (2010) The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial

    PLOS Medicine 7:e1000321.

    https://doi.org/10.1371/journal.pmed.1000321

    • PubMed
    • Google Scholar
28. 1. Geretti AM
    2. White E
    3. Orkin C
    4. Tostevin A
    5. Tilston P
    6. Chadwick D
    7. Leen C
    8. Sabin C
    9. Dunn DT
    10. UK HIV Drug Resistance Database and UK CHIC Study

    (2019) Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance

    Journal of Antimicrobial Chemotherapy 74:746–753.

    https://doi.org/10.1093/jac/dky468

    • PubMed
    • Google Scholar
29. 1. Guaraldi G
    2. Orlando G
    3. Zona S
    4. Menozzi M
    5. Carli F
    6. Garlassi E
    7. Berti A
    8. Rossi E
    9. Roverato A
    10. Palella F

    (2011) Premature age-related comorbidities among HIV-infected persons compared with the general population

    Clinical Infectious Diseases 53:1120–1126.

    https://doi.org/10.1093/cid/cir627

    • PubMed
    • Google Scholar
30. 1. Haïm-Boukobza S
    2. Morand-Joubert L
    3. Flandre P
    4. Valin N
    5. Fourati S
    6. Sayon S
    7. Lavignon M
    8. Simon A
    9. Girard PM
    10. Katlama C
    11. Calvez V
    12. Marcelin AG

    (2011) Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml

    Aids 25:341–344.

    https://doi.org/10.1097/QAD.0b013e3283427de3

    • PubMed
    • Google Scholar
31. 1. Hatano H
    2. Hayes TL
    3. Dahl V
    4. Sinclair E
    5. Lee TH
    6. Hoh R
    7. Lampiris H
    8. Hunt PW
    9. Palmer S
    10. McCune JM
    11. Martin JN
    12. Busch MP
    13. Shacklett BL
    14. Deeks SG

    (2011) A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response

    The Journal of Infectious Diseases 203:960–968.

    https://doi.org/10.1093/infdis/jiq138

    • PubMed
    • Google Scholar
32. 1. Hatano H
    2. Strain MC
    3. Scherzer R
    4. Bacchetti P
    5. Wentworth D
    6. Hoh R
    7. Martin JN
    8. McCune JM
    9. Neaton JD
    10. Tracy RP
    11. Hsue PY
    12. Richman DD
    13. Deeks SG

    (2013a) Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial

    The Journal of Infectious Diseases 208:1436–1442.

    https://doi.org/10.1093/infdis/jit453

    • PubMed
    • Google Scholar
33. 1. Hatano H
    2. Jain V
    3. Hunt PW
    4. Lee TH
    5. Sinclair E
    6. Do TD
    7. Hoh R
    8. Martin JN
    9. McCune JM
    10. Hecht F
    11. Busch MP
    12. Deeks SG

    (2013b) Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells

    The Journal of Infectious Diseases 208:50–56.

    https://doi.org/10.1093/infdis/jis630

    • PubMed
    • Google Scholar
34. 1. Imamichi H
    2. Dewar RL
    3. Adelsberger JW
    4. Rehm CA
    5. O'Doherty U
    6. Paxinos EE
    7. Fauci AS
    8. Lane HC

    (2016) Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy

    PNAS 113:8783–8788.

    https://doi.org/10.1073/pnas.1609057113

    • PubMed
    • Google Scholar
35. 1. Imamichi H
    2. Smith M
    3. Adelsberger JW
    4. Izumi T
    5. Scrimieri F
    6. Sherman BT
    7. Rehm CA
    8. Imamichi T
    9. Pau A
    10. Catalfamo M
    11. Fauci AS
    12. Lane HC

    (2020) Defective HIV-1 proviruses produce viral proteins

    PNAS 117:3704–3710.

    https://doi.org/10.1073/pnas.1917876117

    • PubMed
    • Google Scholar
36. 1. Jacobs JL
    2. Halvas EK
    3. Tosiano MA
    4. Mellors JW

    (2019) Persistent HIV-1 viremia on antiretroviral therapy: measurement and mechanisms

    Frontiers in Microbiology 10:2383.

    https://doi.org/10.3389/fmicb.2019.02383

    • PubMed
    • Google Scholar
37. 1. Jochmans D
    2. Anders M
    3. Keuleers I
    4. Smeulders L
    5. Kräusslich HG
    6. Kraus G
    7. Müller B

    (2010) Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease

    Retrovirology 7:89.

    https://doi.org/10.1186/1742-4690-7-89

    • PubMed
    • Google Scholar
38. 1. Joos B
    2. Fischer M
    3. Kuster H
    4. Pillai SK
    5. Wong JK
    6. Böni J
    7. Hirschel B
    8. Weber R
    9. Trkola A
    10. Günthard HF
    11. Swiss HIV Cohort Study

    (2008) HIV rebounds from latently infected cells, rather than from continuing low-level replication

    PNAS 105:16725–16730.

    https://doi.org/10.1073/pnas.0804192105

    • PubMed
    • Google Scholar
39. 1. Kiselinova M
    2. Geretti AM
    3. Malatinkova E
    4. Vervisch K
    5. Beloukas A
    6. Messiaen P
    7. Bonczkowski P
    8. Trypsteen W
    9. Callens S
    10. Verhofstede C
    11. De Spiegelaere W
    12. Vandekerckhove L

    (2015) HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens

    Journal of Antimicrobial Chemotherapy 3:dkv250.

    https://doi.org/10.1093/jac/dkv250

    • Google Scholar
40. 1. Klatt NR
    2. Chomont N
    3. Douek DC
    4. Deeks SG

    (2013) Immune activation and HIV persistence: implications for curative approaches to HIV infection

    Immunological Reviews 254:326–342.

    https://doi.org/10.1111/imr.12065

    • PubMed
    • Google Scholar
41. 1. Konstantopoulos C
    2. Ribaudo H
    3. Ragland K
    4. Bangsberg DR
    5. Li JZ

    (2015) Antiretroviral regimen and suboptimal medication adherence are associated with low-level human immunodeficiency virus viremia

    Open Forum Infectious Diseases 2:ofu119.

    https://doi.org/10.1093/ofid/ofu119

    • PubMed
    • Google Scholar
42. 1. Li JZ
    2. Etemad B
    3. Ahmed H
    4. Aga E
    5. Bosch RJ
    6. Mellors JW
    7. Kuritzkes DR
    8. Lederman MM
    9. Para M
    10. Gandhi RT

    (2016) The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption

    Aids 30:343–353.

    https://doi.org/10.1097/QAD.0000000000000953

    • PubMed
    • Google Scholar
43. 1. Lohse N
    2. Hansen AB
    3. Pedersen G
    4. Kronborg G
    5. Gerstoft J
    6. Sørensen HT
    7. Vaeth M
    8. Obel N

    (2007) Survival of persons with and without HIV infection in Denmark, 1995-2005

    Annals of Internal Medicine 146:87–95.

    https://doi.org/10.7326/0003-4819-146-2-200701160-00003

    • PubMed
    • Google Scholar
44. 1. Lorenzo-Redondo R
    2. Fryer HR
    3. Bedford T
    4. Kim EY
    5. Archer J
    6. Pond SLK
    7. Chung YS
    8. Penugonda S
    9. Chipman J
    10. Fletcher CV
    11. Schacker TW
    12. Malim MH
    13. Rambaut A
    14. Haase AT
    15. McLean AR
    16. Wolinsky SM

    (2016) Persistent HIV-1 replication maintains the tissue reservoir during therapy

    Nature 530:51–56.

    https://doi.org/10.1038/nature16933

    • PubMed
    • Google Scholar
45. 1. Maldarelli F
    2. Wu X
    3. Su L
    4. Simonetti FR
    5. Shao W
    6. Hill S
    7. Spindler J
    8. Ferris AL
    9. Mellors JW
    10. Kearney MF
    11. Coffin JM
    12. Hughes SH

    (2014) Specific HIV integration sites are linked to clonal expansion and persistence of infected cells

    Science 345:179–183.

    https://doi.org/10.1126/science.1254194

    • PubMed
    • Google Scholar
46. 1. Malnati MS
    2. Scarlatti G
    3. Gatto F
    4. Salvatori F
    5. Cassina G
    6. Rutigliano T
    7. Volpi R
    8. Lusso P

    (2008) A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load

    Nature Protocols 3:1240–1248.

    https://doi.org/10.1038/nprot.2008.108

    • PubMed
    • Google Scholar
47. 1. Martinez-Picado J
    2. Deeks SG

    (2016) Persistent HIV-1 replication during antiretroviral therapy

    Current Opinion in HIV and AIDS 11:417–423.

    https://doi.org/10.1097/COH.0000000000000287

    • PubMed
    • Google Scholar
48. 1. Massanella M
    2. Fromentin R
    3. Chomont N

    (2016) Residual inflammation and viral reservoirs: alliance against an HIV cure

    Current Opinion in HIV and AIDS 11:234–241.

    https://doi.org/10.1097/COH.0000000000000230

    • PubMed
    • Google Scholar
49. 1. McMahon D
    2. Jones J
    3. Wiegand A
    4. Gange SJ
    5. Kearney M
    6. Palmer S
    7. McNulty S
    8. Metcalf JA
    9. Acosta E
    10. Rehm C
    11. Coffin JM
    12. Mellors JW
    13. Maldarelli F

    (2010) Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

    Clinical Infectious Diseases 50:912–919.

    https://doi.org/10.1086/650749

    • PubMed
    • Google Scholar
50. 1. Nicastri E
    2. Palmisano L
    3. Sarmati L
    4. D'Ettorre G
    5. Parisi S
    6. Andreotti M
    7. Buonomini A
    8. Pirillo FM
    9. Narciso P
    10. Bellagamba R
    11. Vullo V
    12. Montano M
    13. Di Perri G
    14. Andreoni M

    (2008) HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens

    Current HIV Research 6:261–266.

    https://doi.org/10.2174/157016208784325010

    • PubMed
    • Google Scholar
51. 1. O'Connor JL
    2. Gardner EM
    3. Mannheimer SB
    4. Lifson AR
    5. Esser S
    6. Telzak EE
    7. Phillips AN
    8. INSIGHT SMART Study Group

    (2013) Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial

    The Journal of Infectious Diseases 208:40–49.

    https://doi.org/10.1093/infdis/jis731

    • PubMed
    • Google Scholar
52. 1. Palmer S
    2. Maldarelli F
    3. Wiegand A
    4. Bernstein B
    5. Hanna GJ
    6. Brun SC
    7. Kempf DJ
    8. Mellors JW
    9. Coffin JM
    10. King MS

    (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

    PNAS 105:3879–3884.

    https://doi.org/10.1073/pnas.0800050105

    • PubMed
    • Google Scholar
53. 1. Pankau MD
    2. Reeves DB
    3. Harkins E
    4. Ronen K
    5. Jaoko W
    6. Mandaliya K
    7. Graham SM
    8. McClelland RS
    9. Matsen Iv FA
    10. Schiffer JT
    11. Overbaugh J
    12. Lehman DA

    (2020) Dynamics of HIV DNA reservoir seeding in a cohort of superinfected kenyan women

    PLOS Pathogens 16:e1008286.

    https://doi.org/10.1371/journal.ppat.1008286

    • PubMed
    • Google Scholar
54. 1. Pardons M
    2. Baxter AE
    3. Massanella M
    4. Pagliuzza A
    5. Fromentin R
    6. Dufour C
    7. Leyre L
    8. Routy JP
    9. Kaufmann DE
    10. Chomont N

    (2019) Single-cell characterization and quantification of translation-competent viral reservoirs in treated and untreated HIV infection

    PLOS Pathogens 15:e1007619.

    https://doi.org/10.1371/journal.ppat.1007619

    • PubMed
    • Google Scholar
55. 1. Pasternak AO
    2. Adema KW
    3. Bakker M
    4. Jurriaans S
    5. Berkhout B
    6. Cornelissen M
    7. Lukashov VV

    (2008) Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA

    Journal of Clinical Microbiology 46:2206–2211.

    https://doi.org/10.1128/JCM.00055-08

    • PubMed
    • Google Scholar
56. 1. Pasternak AO
    2. Jurriaans S
    3. Bakker M
    4. Prins JM
    5. Berkhout B
    6. Lukashov VV

    (2009) Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome

    PLOS ONE 4:e8490.

    https://doi.org/10.1371/journal.pone.0008490

    • PubMed
    • Google Scholar
57. 1. Pasternak AO
    2. de Bruin M
    3. Jurriaans S
    4. Bakker M
    5. Berkhout B
    6. Prins JM
    7. Lukashov VV

    (2012) Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma

    The Journal of Infectious Diseases 206:1443–1452.

    https://doi.org/10.1093/infdis/jis502

    • PubMed
    • Google Scholar
58. 1. Pasternak AO
    2. Lukashov VV
    3. Berkhout B

    (2013) Cell-associated HIV RNA: a dynamic biomarker of viral persistence

    Retrovirology 10:41.

    https://doi.org/10.1186/1742-4690-10-41

    • PubMed
    • Google Scholar
59. 1. Pasternak AO
    2. de Bruin M
    3. Bakker M
    4. Berkhout B
    5. Prins JM

    (2015) High current CD4+ T cell count predicts suboptimal adherence to antiretroviral therapy

    PLOS ONE 10:e0140791.

    https://doi.org/10.1371/journal.pone.0140791

    • PubMed
    • Google Scholar
60. 1. Pasternak AO
    2. Grijsen ML
    3. Wit FW
    4. Bakker M
    5. Jurriaans S
    6. Prins JM
    7. Berkhout B

    (2020) Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART

    JCI Insight 5:e134196.

    https://doi.org/10.1172/jci.insight.134196

    • Google Scholar
61. 1. Pasternak AO
    2. Berkhout B

    (2016) HIV reservoir: finding the right needles in a needlestack

    Cell Host & Microbe 20:280–282.

    https://doi.org/10.1016/j.chom.2016.08.011

    • PubMed
    • Google Scholar
62. 1. Pasternak AO
    2. Berkhout B

    (2018) What do we measure when we measure cell-associated HIV RNA

    Retrovirology 15:13.

    https://doi.org/10.1186/s12977-018-0397-2

    • PubMed
    • Google Scholar
63. 1. Pau AK
    2. George JM

    (2014) Antiretroviral therapy: current drugs

    Infectious Disease Clinics of North America 28:371–402.

    https://doi.org/10.1016/j.idc.2014.06.001

    • PubMed
    • Google Scholar
64. 1. Perelson AS
    2. Essunger P
    3. Cao Y
    4. Vesanen M
    5. Hurley A
    6. Saksela K
    7. Markowitz M
    8. Ho DD

    (1997) Decay characteristics of HIV-1-infected compartments during combination therapy

    Nature 387:188–191.

    https://doi.org/10.1038/387188a0

    • PubMed
    • Google Scholar
65. 1. Pollack RA
    2. Jones RB
    3. Pertea M
    4. Bruner KM
    5. Martin AR
    6. Thomas AS
    7. Capoferri AA
    8. Beg SA
    9. Huang SH
    10. Karandish S
    11. Hao H
    12. Halper-Stromberg E
    13. Yong PC
    14. Kovacs C
    15. Benko E
    16. Siliciano RF
    17. Ho YC

    (2017) Defective HIV-1 proviruses are expressed and can be recognized by cytotoxic T lymphocytes, which shape the proviral landscape

    Cell Host & Microbe 21:494–506.

    https://doi.org/10.1016/j.chom.2017.03.008

    • PubMed
    • Google Scholar
66. 1. Sarmati L
    2. Parisi SG
    3. Montano M
    4. Andreis S
    5. Scaggiante R
    6. Galgani A
    7. Viscione M
    8. Maffongelli G
    9. Ricciardi A
    10. Andreoni C
    11. Boros S
    12. Palù G
    13. Andreoni M

    (2012) Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain

    Journal of Antimicrobial Chemotherapy 67:2932–2938.

    https://doi.org/10.1093/jac/dks331

    • PubMed
    • Google Scholar
67. 1. Schouten J
    2. Wit FW
    3. Stolte IG
    4. Kootstra NA
    5. van der Valk M
    6. Geerlings SE
    7. Prins M
    8. Reiss P
    9. AGEhIV Cohort Study Group

    (2014) Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study

    Clinical Infectious Diseases 59:1787–1797.

    https://doi.org/10.1093/cid/ciu701

    • PubMed
    • Google Scholar
68. 1. Sharaf RR
    2. Li JZ

    (2017) The alphabet soup of HIV reservoir markers

    Current HIV/AIDS Reports 14:72–81.

    https://doi.org/10.1007/s11904-017-0355-y

    • PubMed
    • Google Scholar
69. 1. Sigal A
    2. Kim JT
    3. Balazs AB
    4. Dekel E
    5. Mayo A
    6. Milo R
    7. Baltimore D

    (2011) Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy

    Nature 477:95–98.

    https://doi.org/10.1038/nature10347

    • PubMed
    • Google Scholar
70. 1. Siliciano JD
    2. Kajdas J
    3. Finzi D
    4. Quinn TC
    5. Chadwick K
    6. Margolick JB
    7. Kovacs C
    8. Gange SJ
    9. Siliciano RF

    (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

    Nature Medicine 9:727–728.

    https://doi.org/10.1038/nm880

    • PubMed
    • Google Scholar
71. 1. Trinité B
    2. Zhang H
    3. Levy DN

    (2019) NNRTI-induced HIV-1 protease-mediated cytotoxicity induces rapid death of CD4 T cells during productive infection and latency reversal

    Retrovirology 16:17.

    https://doi.org/10.1186/s12977-019-0479-9

    • PubMed
    • Google Scholar
72. 1. Van Zyl GU
    2. Katusiime MG
    3. Wiegand A
    4. McManus WR
    5. Bale MJ
    6. Halvas EK
    7. Luke B
    8. Boltz VF
    9. Spindler J
    10. Laughton B
    11. Engelbrecht S
    12. Coffin JM
    13. Cotton MF
    14. Shao W
    15. Mellors JW
    16. Kearney MF

    (2017) No evidence of HIV replication in children on antiretroviral therapy

    Journal of Clinical Investigation 127:3827–3834.

    https://doi.org/10.1172/JCI94582

    • PubMed
    • Google Scholar
73. 1. Wagner TA
    2. McLaughlin S
    3. Garg K
    4. Cheung CY
    5. Larsen BB
    6. Styrchak S
    7. Huang HC
    8. Edlefsen PT
    9. Mullins JI
    10. Frenkel LM

    (2014) Proliferation of cells with HIV integrated into Cancer genes contributes to persistent infection

    Science 345:570–573.

    https://doi.org/10.1126/science.1256304

    • PubMed
    • Google Scholar
74. 1. Wang Q
    2. Gao H
    3. Clark KM
    4. Mugisha CS
    5. Davis K
    6. Tang JP
    7. Harlan GH
    8. DeSelm CJ
    9. Presti RM
    10. Kutluay SB
    11. Shan L

    (2021) CARD8 is an inflammasome sensor for HIV-1 protease activity

    Science 371:eabe1707.

    https://doi.org/10.1126/science.abe1707

    • PubMed
    • Google Scholar
75. 1. Williams JP
    2. Hurst J
    3. Stöhr W
    4. Robinson N
    5. Brown H
    6. Fisher M
    7. Kinloch S
    8. Cooper D
    9. Schechter M
    10. Tambussi G
    11. Fidler S
    12. Carrington M
    13. Babiker A
    14. Weber J
    15. Koelsch KK
    16. Kelleher AD
    17. Phillips RE
    18. Frater J
    19. SPARTACTrial Investigators

    (2014) HIV-1 DNA predicts disease progression and post-treatment virological control

    eLife 3:e03821.

    https://doi.org/10.7554/eLife.03821

    • PubMed
    • Google Scholar

Author details

1. Alexander O Pasternak

   Amsterdam UMC, University of Amsterdam, Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam, Netherlands

   Contribution

   Conceptualization, Formal analysis, Investigation, Methodology, Writing - original draft, Writing - review and editing

   For correspondence

   a.o.pasternak@amsterdamumc.nl

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-4097-4251

2. Jelmer Vroom

   Amsterdam UMC, University of Amsterdam, Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam, Netherlands

   Contribution

   Investigation

   Competing interests

   No competing interests declared

3. Neeltje A Kootstra

   Amsterdam UMC, University of Amsterdam, Laboratory of Viral Immune Pathogenesis, Department of Experimental Immunology, Amsterdam, Netherlands

   Contribution

   Data curation

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0001-9429-7754

4. Ferdinand WNM Wit

   1. Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands
   2. Amsterdam UMC, University of Amsterdam, Department of Global Health, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands
   3. HIV Monitoring Foundation, Amsterdam, Netherlands
   4. Amsterdam UMC, University of Amsterdam, Department of Internal Medicine, Amsterdam, Netherlands

   Contribution

   Conceptualization, Methodology

   Competing interests

   No competing interests declared

5. Marijn de Bruin

   1. Health Psychology Group, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom
   2. Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, Netherlands

   Contribution

   Data curation

   Competing interests

   No competing interests declared

6. Davide De Francesco

   Institute for Global Health, University College London, London, United Kingdom

   Contribution

   Data curation

   Competing interests

   No competing interests declared

7. Margreet Bakker

   Amsterdam UMC, University of Amsterdam, Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam, Netherlands

   Contribution

   Resources, Data curation

   Competing interests

   No competing interests declared

8. Caroline A Sabin

   Institute for Global Health, University College London, London, United Kingdom

   Contribution

   Formal analysis, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

9. Alan Winston

   Department of Medicine, Imperial College London, London, United Kingdom

   Contribution

   Data curation

   Competing interests

   No competing interests declared

10. Jan M Prins

    Amsterdam UMC, University of Amsterdam, Department of Internal Medicine, Amsterdam, Netherlands

    Contribution

    Data curation, Project administration, Writing - review and editing

    Competing interests

    No competing interests declared

11. Peter Reiss

    1. Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands
    2. Amsterdam UMC, University of Amsterdam, Department of Global Health, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands
    3. HIV Monitoring Foundation, Amsterdam, Netherlands

    Contribution

    Data curation, Funding acquisition, Project administration, Writing - review and editing

    Competing interests

    No competing interests declared

12. Ben Berkhout

    Amsterdam UMC, University of Amsterdam, Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam, Netherlands

    Contribution

    Conceptualization, Supervision, Funding acquisition, Writing - review and editing

    Competing interests

    No competing interests declared

13. The Co-morBidity in Relation to Aids (COBRA) Collaboration

    Contribution

    Funding acquisition

    Competing interests

    No competing interests declared

    1. P Reiss, Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    2. FWNM Wit, Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    3. J Schouten, Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    4. KW Kooij, Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    5. RA van Zoest, Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    6. BC Elsenga, Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    7. FR Janssen, Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    8. M Heidenrijk, Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    9. W Zikkenheiner, Department of Global Health and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    10. M van der Valk, Division of Infectious Diseases, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    11. NA Kootstra, Department of Experimental Immunology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    12. T Booiman, Department of Experimental Immunology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    13. AM Harskamp-Holwerda, Department of Experimental Immunology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    14. I Maurer, Department of Experimental Immunology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    15. MM Mangas Ruiz, Department of Experimental Immunology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    16. AF Girigorie, Department of Experimental Immunology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    17. J Villaudy, Department of Medical Microbiology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    18. E Frankin, Department of Medical Microbiology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    19. AO Pasternak, Department of Medical Microbiology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    20. B Berkhout, Department of Medical Microbiology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    21. T van der Kuyl, Department of Medical Microbiology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    22. P Portegies, Department of Neurology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    23. BA Schmand, Department of Neurology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    24. GJ Geurtsen, Department of Neurology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    25. JA ter Stege, Department of Neurology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    26. M Klein Twennaar, Department of Neurology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    27. CBLM Majoie, Department of Radiology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    28. MWA Caan, Department of Radiology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    29. T Su, Department of Radiology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    30. K Weijer, Department of Cell Biology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    31. PHLT Bisschop, Division of Endocrinology and Metabolism, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    32. A Kalsbeek, Department of Experimental Neuroendocrinology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    33. M Wezel, Department of Ophthalmology, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    34. I Visser, Department of Psychiatry, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    35. HG Ruhé, Department of Psychiatry, Amsterdam UMC, Universiteit van Amsterdam, Amsterdam, Netherlands
    36. C Franceschi, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna, Bologna, Italy
    37. P Garagnani, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna, Bologna, Italy
    38. C Pirazzini, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna, Bologna, Italy
    39. M Capri, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna, Bologna, Italy
    40. F Dall'Olio, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna, Bologna, Italy
    41. M Chiricolo, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna, Bologna, Italy
    42. S Salvioli, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum Universita di Bologna, Bologna, Italy
    43. J Hoeijmakers, Department of Genetics, Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
    44. J Pothof, Department of Genetics, Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
    45. M Prins, Cluster of Infectious Diseases, research department, GGD Amsterdam/Public Health Service Amsterdam, Amsterdam, Netherlands
    46. M Martens, Cluster of Infectious Diseases, research department, GGD Amsterdam/Public Health Service Amsterdam, Amsterdam, Netherlands
    47. S Moll, Cluster of Infectious Diseases, research department, GGD Amsterdam/Public Health Service Amsterdam, Amsterdam, Netherlands
    48. J Berkel, Cluster of Infectious Diseases, research department, GGD Amsterdam/Public Health Service Amsterdam, Amsterdam, Netherlands
    49. M Totté, Cluster of Infectious Diseases, research department, GGD Amsterdam/Public Health Service Amsterdam, Amsterdam, Netherlands
    50. S Kovalev, Cluster of Infectious Diseases, research department, GGD Amsterdam/Public Health Service Amsterdam, Amsterdam, Netherlands
    51. M Gisslén, Göteborgs Universitet, Gotenburg, Sweden
    52. D Fuchs, Göteborgs Universitet, Gotenburg, Sweden
    53. H Zetterberg, Göteborgs Universitet, Gotenburg, Sweden
    54. A Winston, Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine, London, United Kingdom
    55. J Underwood, Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine, London, United Kingdom
    56. L McDonald, Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine, London, United Kingdom
    57. M Stott, Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine, London, United Kingdom
    58. K Legg, Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine, London, United Kingdom
    59. A Lovell, Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine, London, United Kingdom
    60. O Erlwein, Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine, London, United Kingdom
    61. N Doyle, Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine, London, United Kingdom
    62. C Kingsley, Department of Medicine, Division of Infectious Diseases, Imperial College of Science, Technology and Medicine, London, United Kingdom
    63. DJ Sharp, Department of Medicine, Division of Brain Sciences, The Computational, Cognitive & Clinical Neuroimaging Laboratory, Imperial College of Science, Technology and Medicine, London, United Kingdom
    64. R Leech, Department of Medicine, Division of Brain Sciences, The Computational, Cognitive & Clinical Neuroimaging Laboratory, Imperial College of Science, Technology and Medicine, London, United Kingdom
    65. JH Cole, Department of Medicine, Division of Brain Sciences, The Computational, Cognitive & Clinical Neuroimaging Laboratory, Imperial College of Science, Technology and Medicine, London, United Kingdom
    66. S Zaheri, Stichting HIV Monitoring, Amsterdam, Netherlands
    67. MMJ Hillebregt, Stichting HIV Monitoring, Amsterdam, Netherlands
    68. YMC Ruijs, Stichting HIV Monitoring, Amsterdam, Netherlands
    69. DP Benschop, Stichting HIV Monitoring, Amsterdam, Netherlands
    70. D Burger, Stichting Katholieke Universiteit Nijmegen, Nijmegen, Netherlands
    71. M de Graaff-Teulen, Stichting Katholieke Universiteit Nijmegen, Nijmegen, Netherlands
    72. G Guaraldi, Department of Medical and Surgical Sciences for Children & Adults, Università degli studi di Modena e Reggio Emilia, Modena, Italy
    73. A Bürkle, Department of Biology, Universität Konstanz, Konstanz, Germany
    74. T Sindlinger, Department of Biology, Universität Konstanz, Konstanz, Germany
    75. M Moreno-Villanueva, Department of Biology, Universität Konstanz, Konstanz, Germany
    76. A Keller, Department of Biology, Universität Konstanz, Konstanz, Germany
    77. C Sabin, Research Department of Infection and Population Health, University College London, London, United Kingdom
    78. D de Francesco, Research Department of Infection and Population Health, University College London, London, United Kingdom
    79. C Libert, Inflammation Research Center, Vlaams Instituut voor Biotechnologie, Ghent, Belgium
    80. S Dewaele, Inflammation Research Center, Vlaams Instituut voor Biotechnologie, Ghent, Belgium